CBD Life Sciences Inc (PK) (CBDL) ニュース

it's loi and the dispensary will open in 6 months pennyplayers can't wait that long. Also otc been meh this month, actual cryptos is where it's at for now. All that might change though if it moves on hearing in dec/jan on rescheduling mj into class three drug.

chill dude or dudette............. based on this

am i not allowed to have an opinion or be bullsih on this or any other stock - youre making claims with out proof - i am showing you tangible proof of in my opinion a really fantastic pr!!! all it takes is one - dudes like you always slam us pro stock folk...hadd the same thing with CGAC then last week boooom from no bid to .001 in two days!!! same thing will happen here...i got lots of time - maybe read the pr one or 12 more times.....

https://ih.advfn.com/stock-market/USOTC/CBDL/stock-news/94943443/cbd-life-sciences-inc-cbdl-closes-on-loi-for-pote

mfy hopes lol

LOL based on what? The 167,000 in sales on the income statement or the billions in dilution going on again? Please keep buying they have billions of new shares still to sell.

agreed its a great stock!!

Strong buy at double bottom

more news update coming this one will fly any time soon. No R/S no dilution, huge revenue coming let's break out 0.002 soon

When the company has 4.5 billion a/s to sell. That one bump is all it will see. That is same pattern has before. This is not first time they are doing billions in dilution. Only fools blind to this dilution scam would buy. Wait and see. It will again go to .00001 and be there unstill next r/s.

with the amazing news in the past couple months this should be soaring , i dont get it, i guess buy more lol

i thought the news was gonna send this - i guess we wait

Because that is all this is a vape store. That is why income statement shoed only 167,000 in sales. They have sold billions of shares more then once. Now after r/s a/s is 4.5 billion. Each day buys filled with new shares. No one has again at these levels.

Why does the CBDL address come up as a Strip Mall Unit 108. Google shows it as a VAPE store.

CBD Life Sciences Inc. (CBDL) Closes on LOI for Potential $8 Million Revenue Cannabis DispensaryPress Release | 11/19/2024

With the New York cannabis market projected to surpass $5 billion by 2027, this acquisition positions CBDL for exponential revenue growth and expanded market dominance.

SCOTTSDALE, AZ / ACCESSWIRE / November 19, 2024 / CBD Life Sciences Inc. (OTC PINK:CBDL), a pioneering force in the CBD and cannabis industries, is proud to announce the signing of a pivotal Letter of Intent (LOI) to acquire an interest in a cannabis dispensary located in New York. The dispensary, purchased from Market Wave Capital, LLC, is expected to generate $8 million in annual revenue once operational and marks a transformative moment in CBDL's journey toward industry dominance. Pending financing and state regulatory approvals, the dispensary is slated to open its doors within six months, ushering in a new chapter of accelerated growth and profitability.

A Game-Changing Move in a Booming Industry

The global marijuana dispensary market is on a meteoric rise, projected to grow at a compound annual growth rate (CAGR) of 25.5%, with revenues anticipated to surpass $73.6 billion by 2030. New York, a burgeoning hub for cannabis consumption and sales, presents unparalleled opportunities for growth, thanks to progressive legislation and a rapidly expanding consumer base.

"This acquisition is a monumental milestone for CBD Life Sciences and a testament to our aggressive growth strategy," said Lisa Nelson, President and CEO of CBDL. "The dispensary's location in New York positions us at the epicenter of one of the fastest-growing cannabis markets in the world. With projected revenues of $8 million annually, this venture is set to deliver significant value to our shareholders while opening new doors for expansion into adjacent markets."

Why This Matters for CBDL and Its Investors

The dispensary's strategic location in New York provides immediate access to a cannabis market projected to exceed $5 billion in annual sales by 2027. CBDL is seizing this opportunity at a critical juncture in the industry's evolution, aligning itself with the broader movement toward cannabis legalization and normalization.

For investors, this development underscores the company's ability to execute high-impact initiatives while navigating a highly competitive and regulated market. The acquisition not only bolsters CBDL's revenue potential but also establishes a foundation for future ventures in high-demand sectors, including recreational, medical, and hybrid cannabis markets.

Furthermore, the dispensary is expected to serve as a gateway for CBDL to introduce its own product lines into a retail setting, creating cross-promotional opportunities and fostering brand loyalty among a rapidly growing customer base.

Revenue, Growth, and a Vision for the Future

With potential revenues of $8 million annually, this acquisition is a significant leap forward for CBDL's financial profile. Beyond the immediate economic impact, this strategic move sets the stage for:

Market Diversification: The dispensary adds a robust revenue stream, complementing CBDL's existing portfolio of CBD products.

Future Expansion: Establishing a foothold in New York lays the groundwork for scaling operations to other states as cannabis legalization continues to gain momentum.

Enhanced Shareholder Value: The dispensary's profitability will drive returns for current shareholders while making CBDL an attractive investment for new stakeholders.

Strategic Significance

The acquisition reflects CBDL's forward-thinking approach to growth, as the company positions itself at the intersection of opportunity and innovation. By tapping into the New York cannabis market, CBDL is not just diversifying its portfolio but also creating synergies between its dispensary operations and its existing product lines, including pain creams, nano CBD coffee creamers, and more.

Additionally, the dispensary aligns with CBDL's mission to provide high-quality cannabis solutions while embracing consumer trends and regulatory changes. This move reinforces CBDL's standing as a company that is not only thriving in the present but also building for the future.

A Call to Shareholders and Future Investors

"This is only the beginning," added Nelson. "CBDL's strategic direction is clear: growth, innovation, and value creation. The dispensary will act as a springboard for broader ventures, and we are just getting started in leveraging the opportunities this industry offers."

CBDL invites shareholders and prospective investors to join us on this journey as we solidify our position as a leader in the cannabis and CBD industries. This acquisition underscores our commitment to seizing high-value opportunities and delivering long-term value to our shareholders. More updates to come!

About CBD Life Sciences Inc.

CBD Life Sciences Inc. (OTC PINK:CBDL) is a leading innovator in the CBD and cannabis industries, with a mission to enhance lives through premium-quality products and groundbreaking market strategies. The company's diverse portfolio and forward-thinking initiatives position it as a dynamic force in one of the most exciting and fast-growing industries in the world.

Follow our social media for the latest updates!

X: https://www.x.com/CBDL_StockOTC
Instagram: https://www.instagram.com/cbd.vault
IR Contact: cbdvaultaz@gmail.com

Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.

Contact Information

Lisa Nelson
CEO
cbdvaultaz@gmail.com
4802091720

Related Images

SOURCE: CBD Life Sciences Inc.


View the original press release on accesswire.com
https://www.otcmarkets.com/stock/CBDL/news/CBD-Life-Sciences-Inc-CBDL-Closes-on-LOI-for-Potential-8-Million-Revenue-Cannabis-Dispensary?id=459587

https://www.otcmarkets.com/stock/CBDL/news/CBD-Life-Sciences-Inc-CBDL-Closes-on-LOI-for-Potential-8-Million-Revenue-Cannabis-Dispensary?id=459587

huge buy at ask 0.0004, not bad, Tomorrow we will see good buy at ask 0.0005.

They got rich selling shares to suckers not CBD. The revenues on the income statement were 167,000. Not even enough to buy a house. More billions of shares to be sold to more fools.

big loading

$CBDL How do you think Tom and Lisa Nelson bought that multiple million dollar house a couple years ago? Thank the dumb buyers for that.

They must be getting close to selling 1 billion new shares of the 4.5 billion they increased a/s to. The way they are selling shares. .00001 will come soon.

All the same as it has been since 2021. Same thing all over again. The revenues on last financials. 167K. Billions in dilutions every year for that result.

I couldn't agree with you more all this great news and share price only moves from .0005 down to .0004 for the Company it's more fluff news and wash, rinse, and repeat. total dilution.I pulled out before losing it all.

The dilution never ends here. All they want to do is sell billions of shares. The revenues are tiny. They get rich selling shares not CBD. It will fall to .00001 like before. Then stuck.

Not in the right sector crypto where it is at for now

I find dilution is a big problem, they sold 625mm shares in one month.

news out, but PPS didn't go up.What's wrong with markets?

CBD Life Sciences Inc. (CBDL) Applies for Beer & Liquor License to Sell CBD WinePress Release | 11/13/2024

Company is creating its own wine. Capitalizing on the projected $2.1 billion U.S. CBD-infused beverage market by 2025, CBDL positions itself at the forefront of innovation, unlocking immense revenue potential in the booming CBD alcohol sector.

SCOTTSDALE, AZ / ACCESSWIRE / November 13, 2024 / CBD Life Sciences Inc. (OTC PINK:CBDL), a pioneer in the CBD wellness industry, is thrilled to announce its application for a beer and liquor license, paving the way for its entry into the CBD-infused wine market. This groundbreaking initiative is set to diversify the company's offerings and tap into one of the fastest-growing segments in the cannabis and alcohol industries.

Market Opportunity and Revenue Potential
The global cannabis beverage market is flourishing, with a valuation of $1.16 billion in 2023, projected to soar at a compound annual growth rate (CAGR) of 19.2% from 2024 to 2030. In the U.S. alone, the CBD-infused beverage market is expected to exceed $1.4 billion by 2023, demonstrating an enormous demand for innovative, wellness-focused alcohol alternatives.

The broader cannabis beverage market, including CBD products, is estimated to grow from $4.55 billion in 2021 to a staggering $38.64 billion by 2030, with a CAGR of 27.1%. This trajectory highlights the lucrative potential of CBD-infused wine as an attractive investment and revenue driver for CBDL.

CBDL's Strategic Position
This move into the CBD wine market comes on the heels of a remarkable 1,744% revenue increase for CBD Life Sciences Inc. since February 2024. This growth reflects the company's ability to execute its strategic initiatives and meet consumer demand for premium CBD products effectively. With its beer and liquor license application in process, CBDL is poised to disrupt the wellness and alcohol sectors, further enhancing shareholder value.

"Applying for a beer and liquor license is a monumental milestone for our company," stated Lisa Nelson, President and CEO of CBD Life Sciences Inc. "We are seizing an opportunity to enter an untapped space that bridges the relaxation of wine with the health benefits of CBD. This initiative represents a massive growth opportunity for CBDL, with the potential to create entirely new revenue streams."

The Rise of CBD-Infused Beverages
CBD-infused beverages are rapidly becoming a preferred choice for consumers seeking alternative, functional drinks that support relaxation and well-being without the psychoactive effects of THC. According to market research, more than 50% of consumers in the U.S. have expressed interest in trying CBD beverages, including wines, which offer a sophisticated and wellness-oriented drinking experience.

By leveraging its expertise in CBD product formulation, CBDL plans to launch a premium CBD wine line that combines high-quality ingredients with advanced nanotechnology to enhance bioavailability. The product will cater to a growing demographic seeking healthier, holistic lifestyle options.

What This Means for Investors
The introduction of CBD-infused wines represents a bold leap forward for CBDL. Industry analysts estimate that cannabis beverages, including CBD-infused options, could account for up to 20% of the overall cannabis market by 2030. This shift could translate into billions of dollars in revenue, solidifying CBDL's leadership in the wellness and CBD industries.

With a focus on premium product innovation, distribution partnerships, and regulatory compliance, CBDL is positioning itself as a dominant player in this burgeoning market. This initiative also lays the groundwork for future expansion into other CBD alcohol categories, such as spirits, seltzers, and beers, amplifying the company's growth potential.

Consumer and Industry Impact
CBDL's foray into the CBD wine market is expected to resonate strongly with millennials and health-conscious consumers who value authenticity, wellness, and quality in their beverage choices. This new product line will provide consumers with a unique way to enjoy CBD while enhancing their social and relaxation experiences.

Furthermore, CBD-infused alcohol represents a game-changing opportunity to redefine the wine industry by introducing a wellness-centric alternative to traditional alcoholic beverages. CBDL aims to set a new standard of excellence with its commitment to innovation and quality.

Looking Ahead
CBD Life Sciences Inc. will provide updates on beer and liquor clients such as restaurants, bars, liquor stores and product launch timeline as milestones are achieved. Shareholders can look forward to seeing this transformative initiative come to life in the months ahead.

About CBD Life Sciences Inc.
CBD Life Sciences Inc. is a cutting-edge leader in the CBD and wellness industry, offering a diverse range of innovative products designed to enhance consumer health and well-being. From CBD-infused creams to cutting-edge beverages, CBDL continues to push the boundaries of what is possible in the CBD space.

Follow our social media for the latest updates!

X: https://www.x.com/CBDL_StockOTC
Instagram: https://www.instagram.com/cbd.vault
IR Contact: cbdvaultaz@gmail.com

Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.

Contact Information:
Lisa Nelson
CEO
cbdvaultaz@gmail.com
4802091720

SOURCE: CBD Life Sciences Inc.


View the original press release on accesswire.com
https://www.otcmarkets.com/stock/CBDL/news/CBD-Life-Sciences-Inc-CBDL-Applies-for-Beer--Liquor-License-to-Sell-CBD-Wine?id=458899

$CBDL CBD Life Sciences Inc. (CBDL) Applies for Beer & Liquor License to Sell CBD Wine


https://www.accesswire.com/941997/cbd-life-sciences-inc-cbdl-applies-for-beer-liquor-license-to-sell-cbd-wine

Company is creating its own wine. Capitalizing on the projected $2.1 billion U.S. CBD-infused beverage market by 2025, CBDL positions itself at the forefront of innovation, unlocking immense revenue potential in the booming CBD alcohol sector.

SCOTTSDALE, AZ / ACCESSWIRE / November 13, 2024 / CBD Life Sciences Inc. (OTC PINK:CBDL), a pioneer in the CBD wellness industry, is thrilled to announce its application for a beer and liquor license, paving the way for its entry into the CBD-infused wine market. This groundbreaking initiative is set to diversify the company's offerings and tap into one of the fastest-growing segments in the cannabis and alcohol industries.

Market Opportunity and Revenue Potential
The global cannabis beverage market is flourishing, with a valuation of $1.16 billion in 2023, projected to soar at a compound annual growth rate (CAGR) of 19.2% from 2024 to 2030. In the U.S. alone, the CBD-infused beverage market is expected to exceed $1.4 billion by 2023, demonstrating an enormous demand for innovative, wellness-focused alcohol alternatives.

The broader cannabis beverage market, including CBD products, is estimated to grow from $4.55 billion in 2021 to a staggering $38.64 billion by 2030, with a CAGR of 27.1%. This trajectory highlights the lucrative potential of CBD-infused wine as an attractive investment and revenue driver for CBDL.

CBDL's Strategic Position
This move into the CBD wine market comes on the heels of a remarkable 1,744% revenue increase for CBD Life Sciences Inc. since February 2024. This growth reflects the company's ability to execute its strategic initiatives and meet consumer demand for premium CBD products effectively. With its beer and liquor license application in process, CBDL is poised to disrupt the wellness and alcohol sectors, further enhancing shareholder value.

"Applying for a beer and liquor license is a monumental milestone for our company," stated Lisa Nelson, President and CEO of CBD Life Sciences Inc. "We are seizing an opportunity to enter an untapped space that bridges the relaxation of wine with the health benefits of CBD. This initiative represents a massive growth opportunity for CBDL, with the potential to create entirely new revenue streams."

The Rise of CBD-Infused Beverages
CBD-infused beverages are rapidly becoming a preferred choice for consumers seeking alternative, functional drinks that support relaxation and well-being without the psychoactive effects of THC. According to market research, more than 50% of consumers in the U.S. have expressed interest in trying CBD beverages, including wines, which offer a sophisticated and wellness-oriented drinking experience.

By leveraging its expertise in CBD product formulation, CBDL plans to launch a premium CBD wine line that combines high-quality ingredients with advanced nanotechnology to enhance bioavailability. The product will cater to a growing demographic seeking healthier, holistic lifestyle options.

What This Means for Investors
The introduction of CBD-infused wines represents a bold leap forward for CBDL. Industry analysts estimate that cannabis beverages, including CBD-infused options, could account for up to 20% of the overall cannabis market by 2030. This shift could translate into billions of dollars in revenue, solidifying CBDL's leadership in the wellness and CBD industries.

With a focus on premium product innovation, distribution partnerships, and regulatory compliance, CBDL is positioning itself as a dominant player in this burgeoning market. This initiative also lays the groundwork for future expansion into other CBD alcohol categories, such as spirits, seltzers, and beers, amplifying the company's growth potential.

Consumer and Industry Impact
CBDL's foray into the CBD wine market is expected to resonate strongly with millennials and health-conscious consumers who value authenticity, wellness, and quality in their beverage choices. This new product line will provide consumers with a unique way to enjoy CBD while enhancing their social and relaxation experiences.

Furthermore, CBD-infused alcohol represents a game-changing opportunity to redefine the wine industry by introducing a wellness-centric alternative to traditional alcoholic beverages. CBDL aims to set a new standard of excellence with its commitment to innovation and quality.

Looking Ahead
CBD Life Sciences Inc. will provide updates on beer and liquor clients such as restaurants, bars, liquor stores and product launch timeline as milestones are achieved. Shareholders can look forward to seeing this transformative initiative come to life in the months ahead.

I see the never ending dilution continues. They probably by now dumped over a billion of the 4.5 billion a/s.

Just like the past. Have on day of big volume that caused a short spike in price. Then as the company keeps diluting. Down it goes. Maybe it could pop one more time but doubtful as massive dilution. Spare me the no dilution. All the same said before. Then financials will show it is billions. Just like the past.

They never say on Pr's what revenues are now or gong to be. Last income statement showed 167,000. Billions in dilution. Even if they did 1 million. It's over valued. A big if considering all the places selling cbd products. They are a no body and revenues show that. It's why they get rich selling billions of shares not products. Same bs as always with them.

Maybe like before but will neve last long. Just too much dilution. By the time they sell all 4.5 billion shares. Same as before .00001 and stuck until next rs. To ignore the past is to be another shareholder stuck at .00001. All before this r.s were and lost.

$CBDL CBD Life Sciences, Inc. (CBDL) Positioned for Unmatched Growth as Trump Welcomes Weed Legalization and Federal Rescheduling


https://www.accesswire.com/939772/cbd-life-sciences-inc-cbdl-positioned-for-unmatched-growth-as-trump-welcomes-weed-legalization-and-federal-rescheduling

The global cannabis market size was valued at USD 43.72 billion in 2022 and is projected to grow from USD 57.18 billion in 2023 to USD 444.34 billion by 2030, exhibiting a CAGR of 34.03% during the forecast period. North America dominated the global market with a share of 81.79% in 2022.

SCOTTSDALE, AZ / ACCESSWIRE / November 7, 2024 / With Former President Donald Trump's recent support for cannabis legalization in key U.S. states and calls to reclassify cannabis as a Schedule III drug, CBD Life Sciences, Inc. (OTC PINK:CBDL) is primed to accelerate its growth in the rapidly expanding cannabis and CBD market. This evolving regulatory environment is expected to unlock powerful revenue streams for CBDL, giving the company a strong competitive edge in an industry poised to reach unprecedented heights.

Major Market Opportunity: Riding the $100 Billion Wave

The U.S. cannabis market is projected to exceed $100 billion by 2030, fueled by widespread voter and legislative support. Trump's endorsement, including a personal commitment to vote "yes" on Florida's Amendment 3 to legalize recreational cannabis, signals bipartisan momentum for cannabis acceptance-a shift that could propel federal rescheduling and facilitate financial growth opportunities across the industry. As cannabis becomes more accessible, CBDL is strategically positioned to deliver innovative products that appeal to a broad consumer base, from wellness enthusiasts to medical patients.

CEO Lisa Nelson: "CBDL Ready to Capture Expansive Market Growth"

"For CBDL, this is a historic moment particularly as the company is currently in a Letter of Intent (LOI) with a cannabis dispensary, positioning itself to capitalize on the growing wave of cannabis legalization." says CEO Lisa Nelson. "With Trump having such significant support from both the public and key political leaders, the market potential is staggering. CBDL's strategic growth plan is designed to capture both the economic impact of increased accessibility and the opportunity to reach millions of new customers nationwide." This moment is especially historic as CBDL is currently in the middle of a Letter of Intent (LOI) with a cannabis dispensary, which aligns perfectly with this new wave of support for cannabis legalization."

CBDL's approach includes product innovation focused on high-quality CBD and cannabis-infused offerings tailored to meet the diverse needs of consumers. As more states pass cannabis-friendly laws, CBDL's distribution channels will expand, enabling the company to maximize its reach in high-demand markets and set new revenue records.

Unlocking Financial Pathways and Reducing Market Barriers

Rescheduling cannabis would not only open more avenues for scientific research but also allow CBD companies like CBDL to benefit from traditional financial and banking services. This anticipated regulatory easing means lower costs, streamlined operations, and increased scalability for CBDL-each of which has a direct impact on shareholder value and revenue growth. With a supportive regulatory environment, CBDL is expected to experience accelerated revenue increases, while establishing a reputation as a leader in research-backed, health-focused cannabis products.

Growing Market Support and Consumer Demand

CBDL's market expansion is also driven by strong consumer support: a recent Pew Research survey revealed that 88% of Americans favor cannabis legalization for either medical or recreational use, with 42% seeing it as a step toward a fairer criminal justice system. This shifting public opinion reflects a robust and growing market, allowing CBDL to target both new and existing consumers across recreational, medical, and wellness sectors. By leveraging this unprecedented demand, CBDL is well-positioned to introduce unique products to fulfill evolving consumer preferences and capitalize on the high-growth potential in this industry.

Link to Article: https://www.usatoday.com/story/news/politics/2024/11/05/donald-trump-marijuana-weed-cannabis-legalization-medical-recreational-election/75970501007/

Can you linked here?

ready to take off again.

they tweeted that today?

OTCMKTS: $CBDL BIG NEWS COMING

$CBDL close in getting the Armed Forces deal closed. Our product of the horse paste is taking off! Walmart orders are shipping out the door. More news coming Stay tuned

OTCMKTS: $CBDL close in getting the Armed Forces deal closed. CBD Life Sciences Ord Shs product of the horse paste is taking off! Walmart orders are shipping out the door

Yes. Safe to say nothing changed here. Massive dilution again.

So safe to say you missed the latest pop❓️

The only way to make money here is doing that. What I have seen though. Doing it one time too many as it drops to .00001 and done. The dilution here has never ended and never will. The revenues after 4 years so tiny vs the billions and billions in dilution. Nothing has changed here. All the same posts telling me same things as before. All were wrong. Good luck timing this. As selling always competes with dilution selling.

I don't care dilution or not, I just do buy low and sell high. I re buy in at 0.0006, will sell after 0.001.

Only OTCN is dilution MM?

I think Harris is more pro on Cannabis and CBD then Trump

Feel free to explain your rationale, but please, keep it on topic regarding $CBDL.

If Harris wins we run hard if not we hit .0001 My take on it.

Every time they increase the A/s to billions. People argue they are not diluting. Every time wrong. Nothing has changed. Look at price after the r/s. No one had 100's of millions of shares to sell. Know who has billions to sell yet again. The company. All this is another repeat of the same thing. The revenues are so tiny. The o/s used to be over 40 billion. Nothing can justify billions sold when revenues under 200K. Even if they can ever sell millions in sales. A long way from that. They still make more selling shares. Ignore the track record and lose. Like many have thinking they would grow big revenues. CBD is a very competitive market. They will never sell enough to justify what they have done to shareholders.

otcn on ask

Don’t know. Some people are saying they’re diluting

I tried to get in this one last week and been away for a few days but I saw it rocketing...so what caused it to drop again, was it news or just the normal correction?

#PowerHour $CBDL